Ranbaxy Recalls Nitrofurantoin From U.S. Due to Remote Possibility Of Non-conformity And Adverse Reactions
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - In yet another move that could raise doubts about the quality of its drugs, Ranbaxy has announced a voluntary recall of its antibiotic nitrofurantoin capsules from the U.S. market. This is the second voluntary drug recall made by Ranbaxy in two years, the first being gabapentin tablets called back in 2007
You may also be interested in...
Cipla’s Manufacturing Units In India Under U.S. FDA Lens; Inspectional Observations Issued
MUMBAI - U.S. FDA conducted inspections of three manufacturing sites belonging to Indian drug maker Cipla and issued nine to 10 "Inspectional Observations" on various manufacturing issues. The manufacturing sites inspected by FDA are in Goa, Kurkumbh and Bangalore
U.S. FDA Nails Ranbaxy On Charges Of Falsifying Data; Halts All Application Reviews From Paonta Sahib Plant
MUMBAI - India's largest drug maker Ranbaxy received a body blow after the U.S. Food and Drug Administration initiated a new regulatory action against the company's Paonta Sahib-based manufacturing plant in India. The drug regulator halted review of drug applications from the manufacturing plant due to evidence of falsified data and invoked the Application Integrity Policy
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).